FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer reports their earnings Tuesday, Jan. 31, 2023.
Pfizer expects revenue from both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound. That drop was anticipated by analysts as the drugmaker moves from supplying governments through big contracts to selling both products on the commercial market. Commercial sales of the vaccine and treatment are expected to start later this year in the U.S. While revenue from both will fall in 2023, analysts still expect the vaccine and treatment to each contribute billions of dollars in annual sales for the next several years.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: